AstraZeneca’s Tagrisso (osimertinib) Recommended for EU Approval in Unresectable EGFR-Mutated Lung Cancer

AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the European Union (EU) for the treatment of adult patients with ...

November 19, 2024 | Tuesday | News
Fate Therapeutics Presents Promising Initial Data for FT819 in Lupus Nephritis at ACR Convergence

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent s...

November 19, 2024 | Tuesday | News
Agilent Launches Mito-rOCR Assay Kit for Streamlined Mitochondrial Function Analysis

Agilent Technologies Inc. (NYSE: A) announces the new Mito-rOCR Assay Kit. This easy and streamlined end-to-end solution makes sophisticated anal...

November 15, 2024 | Friday | News
EMA CHMP Issues Positive Opinion for Lecanemab in Early Alzheimer’s Disease

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...

November 15, 2024 | Friday | News
EMA Committee Recommends Approval of Sarclisa in Combination with VRd for Transplant-Ineligible Multiple Myeloma

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval ...

November 15, 2024 | Friday | News
Gilead’s Lenacapavir Demonstrates Strong Efficacy and High Adherence in Phase 3 PURPOSE 2 Trial for HIV Prevention

Gilead Sciences, Inc. (Nasdaq: GILD) presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is stu...

November 14, 2024 | Thursday | News
FDA Grants Historic Approval to PTC Therapeutics’ KEBILIDI™—First Gene Therapy Directly Delivered to the Brain for AADC Deficiency

- First-ever FDA approval for gene therapy directly administered to the brain - - Priority review voucher granted - - Broad label including children an...

November 14, 2024 | Thursday | News
GenScript Biotech Global Forum 2024: Paving the Way for Innovation and Investment in Cell and Gene Therapy

- The global cell and gene therapy (CGT) industry is poised for remarkable growth, driven by significant advances in life sciences and robust investments...

November 14, 2024 | Thursday | News
TrakCel's OCELLOS Platform Chosen to Support Five Key Cell Therapy Products in 2024, Streamlining CGT Supply Chain Management

TrakCel, a provider of integrated cell and gene therapy (CGT) orchestration solutions for the precise management, control and tracking of CGTs has announce...

November 13, 2024 | Wednesday | News
New Survey Reveals Critical Gaps in Care for Gynaecologic Cancer Patients, Highlighting Unmet Needs in Treatment Access and Support

GSK plc (LSE/NYSE: GSK) announced the results of a GSK-sponsored multinational survey designed to raise awareness of challenges that people with gynaecolog...

November 13, 2024 | Wednesday | News
Abbisko's Phase 3 Study of Pimicotinib Shows Statistically Significant Efficacy in Treating Tenosynovial Giant Cell Tumor (TGCT)

Abbisko announced that the Phase 3 MANEUVER study evaluating pimicotinib in the treatment of tenosynovial giant cell tumor (TGCT) achieved statistically si...

November 12, 2024 | Tuesday | News
Fate Therapeutics Unveils Promising Preclinical Data for FT836, a Next-Generation iPSC-Derived CAR T-Cell Therapy Targeting MICA/B at SITC 2024

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripot...

November 12, 2024 | Tuesday | News
Dragonfly Therapeutics to Present Groundbreaking Preclinical Data on DF6215 and DF9001 at SITC 2024

 a clinical-stage biotechnology company developing novel immunotherapies, announced the company will deliver poster presentations at the Society for I...

November 08, 2024 | Friday | News
IASO Biotherapeutics’ Anti-BCMA CAR-T Therapy Fucaso™ Shows Strong Efficacy in Treating Relapsed/Refractory Multiple Myeloma in Phase 1b/2 Study Published in JAMA Oncology

IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell ther...

November 08, 2024 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close